{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:07:20Z","timestamp":1785413240911,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:01:26Z","timestamp":1773817286000},"page":"637-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-9755","authenticated-orcid":false,"given":"Timothy","family":"Riddles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne J","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-0805","authenticated-orcid":false,"given":"Ieuan E S","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.03.011_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17534666241297877","article-title":"Modulator-refractory cystic fibrosis: defining the scope and challenges of an emerging at-risk population","volume":"18","author":"Somerville","year":"2024","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.011_bib0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.011_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-3476(85)80511-4","article-title":"Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome","volume":"107","author":"Tablan","year":"1985","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.jcf.2026.03.011_bib0004","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970-1989","volume":"143","author":"Corey","year":"1996","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.011_bib0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2012.12.006","article-title":"Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients","volume":"12","author":"Waters","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.011_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcf.2023.09.016","article-title":"When is Burkholderia cepacia complex truly eradicated in adults with cystic fibrosis? A 20-year follow up study","volume":"23","author":"Tewkesbury","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2026.03.011_bib0007","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1513\/AnnalsATS.202003-204OC","article-title":"Clinical outcomes associated with burkholderia cepacia complex infection in patients with cystic fibrosis","volume":"17","author":"Somayaji","year":"2020","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.jcf.2026.03.011_bib0008","unstructured":"Australian CF Data Registry Annual Report (2023). https:\/\/www.cysticfibrosis.org.au\/wp-content\/uploads\/2024\/07\/ACFDR_2023_Annual-Report.pdf (Accessed 22\/11\/2025)."},{"issue":"1","key":"10.1016\/j.jcf.2026.03.011_bib0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.chest.2022.02.007","article-title":"Managing pulmonary infection in adults with Cystic fibrosis: adult Cystic Fibrosis Series","volume":"162","author":"Green","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.011_bib0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2006.10.007","article-title":"Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center","volume":"6","author":"Kennedy","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.011_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ppul.26359","article-title":"Cepacia syndrome in cystic fibrosis: a systematic review of the literature and possible new perspectives in treatment","volume":"58","author":"Dacc\u00f2","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jcf.2026.03.011_bib0012","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1128\/JCM.01360-13","article-title":"Factors influencing acquisition of burkholderia cepacia complex organisms in patients with cystic fibrosis","volume":"51","author":"Ramsay","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.011_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-018-0594-8","article-title":"Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients","volume":"18","author":"Garcia","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.011_bib0014","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.011_bib0016","first-page":"1","article-title":"Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor\/tezacaftor\/ivacaftor: now is not the time to lower the guard","volume":"12","author":"Evans","year":"2025","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.011_bib0017","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.resmic.2008.01.001","article-title":"Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand","volume":"159","author":"Kidd","year":"2008","journal-title":"Res Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.011_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1164\/rccm.201002-0203OC","article-title":"Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections","volume":"183","author":"Zlosnik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2\u20133","key":"10.1016\/j.jcf.2026.03.011_bib0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijmm.2004.06.022","article-title":"Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis: genome evolution, interactions and adaptation","volume":"294","author":"Eberl","year":"2004","journal-title":"Int J Med Microbiol"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.011_bib0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1034\/j.1399-3062.2001.003003149.x","article-title":"Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis?","volume":"3","author":"Lipuma","year":"2001","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.011_bib0021","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/thx.2003.010801","article-title":"Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation","volume":"59","author":"De Soyza","year":"2004","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jcf.2026.03.011_bib0022","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.healun.2023.02.001","article-title":"Post-transplant outcomes among cystic fibrosis patients undergoing lung transplantation colonized by Burkholderia: a single center cohort study","volume":"42","author":"Gauvreau","year":"2023","journal-title":"J Hear Lung Transplant"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:32:04Z","timestamp":1785411124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000561"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}